{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:57:22Z","timestamp":1773320242496,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Tenofovir\/emtricitabine (TDF\/FTC) and abacavir\/lamivudine (ABC\/3TC) are widely used with ritonavir (RTV)\u2010boosted protease inhibitors (PIs) as first\u2010line highly active antiretroviral therapy (HAART), but there is conflicting evidence on their relative efficacy. The ACTG 5202 and BICOMBO trials suggested higher efficacy for TDF\/FTC, whereas the HEAT trial showed no efficacy difference between the nucleoside reverse transcriptase inhibitor (NRTI) backbones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic MEDLINE search identified 21 treatment arms in 12 clinical trials of 5168 antiretroviral\u2010na\u00efve patients, where TDF\/FTC (<jats:italic>n<\/jats:italic>=3399) or ABC\/3TC (<jats:italic>n<\/jats:italic>=1769) was used with RTV\u2010boosted PI. For each NRTI backbone and RTV\u2010boosted PI, the percentage of patients with viral load &lt;50 HIV\u20101 RNA copies\/mL at week 48 by standardized Intent to Treat, Time to Loss of Virological Failure (ITT TLOVR) analysis were combined using inverse\u2010variance weighting. The effect of baseline HIV RNA, CD4 cell count and choice of NRTI backbone were examined using a weighted analysis of covariance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across all the trials, HIV RNA suppression rates were significantly higher for those with baseline viral load below 100\u2003000\u2003copies\/mL (77.2%) <jats:italic>vs<\/jats:italic>. above 100\u2003000\u2003copies\/mL (70.9%) (<jats:italic>P<\/jats:italic>=0.0005). For the trials of lopinavir\/ritonavir (LPV\/r), atazanavir\/ritonavir (ATV\/r) and fosamprenavir\/ritonavir (FAPV\/r) using either TDF\/FTC or ABC\/3TC, the HIV RNA responses were significantly lower when ABC\/3TC was used, relative to TDF\/FTC, for all patients (<jats:italic>P<\/jats:italic>=0.0015) and for patients with baseline viral load &lt;100\u2003000\u2003copies\/mL (70.1%<jats:italic>vs<\/jats:italic>. 80.6%, <jats:italic>P<\/jats:italic>=0.0161), and was borderline for those with viral load &gt;100\u2003000\u2003copies\/mL (67.5%<jats:italic>vs<\/jats:italic>. 71.5%, <jats:italic>P<\/jats:italic>=0.0523).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This systematic meta\u2010regression analysis suggests higher efficacy for first\u2010line use of a TDF\/FTC NRTI backbone with boosted PIs, relative to use of ABC\/3TC. However, this effect may be confounded by differences between the trials in terms of baseline characteristics, patient management or adherence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00724.x","type":"journal-article","created":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T02:24:54Z","timestamp":1246501494000},"page":"527-535","source":"Crossref","is-referenced-by-count":31,"title":["Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first\u2010line boosted highly active antiretroviral therapy based on protease inhibitors: meta\u2010regression analysis of 12 clinical trials in 5168 patients"],"prefix":"10.1111","volume":"10","author":[{"given":"A","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.555"},{"key":"e_1_2_5_3_2","unstructured":"SaxP TierneyC CollierAet al. ACTG 5202: shorter time to virologic failure (VF) with abacavir\/lamivudine (ABC\/3TC) than tenofovir\/emtricitabine (TDF\/FTC) as part of combination therapy in treatment\u2010na\u00efve subjects with screening HIV RNA >100 000 c\/mL.AIDS 2008 \u2013 17th International AIDS Conference. Mexico City August 2008 [Abstract THAB0303]."},{"key":"e_1_2_5_4_2","unstructured":"MartinezE ArranzJ PodzamczerDet al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabinevs. abacavir plus lamivudine in patients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO Study.4th IAS Conference on HIV Pathogenesis Treatment And Prevention. Sydney Australia July 2007 [Abstract WESS101]."},{"key":"e_1_2_5_5_2","unstructured":"SmithK FineD PatelPet al. Efficacy and safety of abacavir\/lamivudine compared to tenofovir\/emtricitabine in combination with once\u2010daily lopinavir\u2013ritonavir through 48 weeks in the HEAT Study.15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston MA February 2008 [Abstract 774]."},{"key":"e_1_2_5_6_2","unstructured":"US Department of Health and Human Services Food and Drug Administration and Center for Drug Evaluation and Research.Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements \u2013 Clinical Considerations for Accelerated and Traditional Approval. Available athttp:\/\/www.fda.gov\/CDER\/GUIDANCE\/3647fnl.pdf(accessed 15 August 2007)."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/135965350501000310","article-title":"Discordant conclusions from HIV efficacy trials \u2013 an evaluation of efficacy endpoints","volume":"10","author":"Hill A","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_5_8_2","unstructured":"WalmsleyS RuxrungthamK SlimJet al. The Gemini Study: saquinavir\/r (SQV\/r)vs. lopinavir (LPV\/r) plus emtricitabine\/tenofovir (FTC\/TDF) as initial therapy in HIV\u20101\u2010infected patients.European AIDS Clinical Society (EACS). Madrid November 2007 [Abstract PS1\/4]."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830285fb"},{"key":"e_1_2_5_10_2","first-page":"476","article-title":"The KLEAN Study of fosamprenavir\u2013ritonavir vs. lopinavir\u2013ritonavir, each in combination with abacavir\u2013lamivudine, for initial treatment of HIV infection over 48 weeks","volume":"368","author":"Eron J","year":"2006","journal-title":"a randomized non-inferiority trial"},{"key":"e_1_2_5_11_2","unstructured":"SmithK WeinbergW DeJesusEet al. Once\u2010daily fosamprenavir or atazanavir both boosted by ritonavir 100\u2003mg plus tenofovir\/emtricitabine combination tablet: a planned week 24 interim analysis of the ALERT Study.8th International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2006 [Abstract P1]."},{"key":"e_1_2_5_12_2","first-page":"5","article-title":"Fosamprenavir or atazanavir with ritonavir 100\u2003mg, plus tenofovir\/emtricitabine, for the initial treatment of HIV infection","volume":"5","author":"Smith K","year":"2008","journal-title":"48 week results of ALERT"},{"key":"e_1_2_5_13_2","unstructured":"MolinaJM VillanuevaJ EchevarriaJet al. Efficacy and safety of boosted once\u2010daily atazanavir and twice\u2010daily lopinavir regimens in treatment\u2010na\u00efve HIV\u20101\u2010infected subjects. CASTLE: 48\u2010week results.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Presentation 37]."},{"key":"e_1_2_5_14_2","unstructured":"CooperD ZajdenvergR RuxrungthamK SchererJ ChavesR. Efficacy and safety of two doses of tipranavir\/ritonavirvs. lopinavir\/ritonavir\u2010based therapy in antiretroviral\u2010na\u00efve patients: results of BI 1182.33.8th International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2006 [Abstract PL13.4]."},{"key":"e_1_2_5_15_2","first-page":"1529","article-title":"SOLO","volume":"18","author":"Gathe J","year":"2004","journal-title":"48-week efficacy and safety comparison of once-daily fosamprenavir\/ritonavir vs. twice-daily nelfinavir in na\u00efve HIV-1-infected patients"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000242449.67155.1a"},{"key":"e_1_2_5_17_2","unstructured":"GatheJ DaSilvaB LoutfyMet al. Study M05\u2010730 primary efficacy results at week 48: phase 3 randomized open\u2010label study of lopinavir\u2013ritonavir (LPV\/r) tablets once\u2010daily (OD)vs. twice\u2010daily (BID) co\u2010administered with tenofovir (TDF) plus emtricitabine (FTC) in antiretroviral na\u00efve (ARV) HIV\u20101\u2010infected subjects.15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston MA February 2008 [Abstract 775]."},{"key":"e_1_2_5_18_2","unstructured":"HicksC De JesusE WohlD LiaoQ PappaK LancasterT.Once\u2010daily fosamprenavir boosted with either 100\u2003mg or 200\u2003mg of ritonavir along with abacavir\/lamivudine: 48 week safety and efficacy results from COL100758.11th European AIDS Conference. Madrid Spain October 2007 [Abstract PS 7.01]."},{"key":"e_1_2_5_19_2","first-page":"152","article-title":"Once daily abacavir\/lamivudine and ritonavir\u2010boosted atazanavir for the treatment of HIV\u20101 infection in antiretroviral na\u00efve patients","volume":"9","author":"Elion R","year":"2008","journal-title":"a 48 week pilot study"},{"key":"e_1_2_5_20_2","first-page":"2095","article-title":"(ACTG Study 5142 Team). Class\u2010sparing regimens for initial treatment of HIV\u20101 infection","volume":"358","author":"Riddler S","journal-title":"N Engl J Med"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_5_22_2","unstructured":"MalanN KrantzE NealD KastangoK FrederickD MathewM.Efficacy and safety of atazanavir with and without ritonavir in antiretroviral\u2010na\u00efve subjects. BMS089: 48\u2013week results.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 107LB]."},{"key":"e_1_2_5_23_2","unstructured":"BartlettJ ChenS QuinnJ WulfsohnM.Overview of time to loss of virologic response (TLOVR) outcomes between efavirenz\u2010based regimens in ART\u2010na\u00efve adults.16th International AIDS Conference. Toronto Canada August 2006 [Abstract THPE0111]."},{"key":"e_1_2_5_24_2","unstructured":"SquiresK YoungB DeJesusEet al. Atazanavir\/ritonavir (ATV\/r) plus abacavir\/lamivudine (ABC\/3TC) in antiretroviral (ART)\u2010na\u00efve HIV\u20101\u2010infected HLA\u2010B*5701 negative subjects demonstrates efficacy and safety: the ARIES Trial.48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20101250a]."},{"key":"e_1_2_5_25_2","unstructured":"MillsA NelsonM JayaweeraDet al. Efficacy and safety of darunavir\/ritonavir 800\/100\u2003mg once\u2010dailyvs. lopinavir\u2013ritonavir in treatment\u2010na\u00efve HIV\u20101\u2010infected patients at 96 weeks: ARTEMIS (TMC114\u2010C211).48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20101250c]."},{"key":"e_1_2_5_26_2","unstructured":"MolinaJ Andrade\u2010VillanuevaJ EchevarriaJet al. Atazanavir\/ritonavirvs. lopinavir\u2013ritonavir in antiretroviral na\u00efve HIV\u20101\u2010infected patients: CASTLE 96 week efficacy and safety.48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20101250d]."},{"key":"e_1_2_5_27_2","unstructured":"MolinaJ WilkinA DomingoPet al. Once\u2010dailyvs. twice daily lopinavir\/ritonavir in antiretroviral\u2010na\u00efve patients: 96 week results.3rd IAS Conference on HIV Pathogenesis and Treatment. Rio De Janeiro Brazil July 2005 [Abstract WePe12.3C 12]."},{"key":"e_1_2_5_28_2","unstructured":"YoungB SmithK PatelPet al. Characterisation of virological failure over 96 weeks by drug resistance and antiviral response in ART na\u00efve patients receiving abacavir\/lamivudine (ABC\/3TC) or tenofovir\/emtricitabine (TDF\/FTC) each with lopinavir\/ritonavir QD in the HEAT Trial.48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20104053]."},{"key":"e_1_2_5_29_2","unstructured":"DeJesusE SloanL SensionM LiaoQ OieK HicksC.96\u2010week efficacy\/safety data comparing two doses of ritonavir (\/r) to boost once\u2010daily fosamprenavir (FPV) used in combination with abacavir (ABC)\/lamivudine (3TC).48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20101246]."},{"key":"e_1_2_5_30_2","unstructured":"PappaK HaB BrothersCet al. Six abacavir\/lamivudine (ABC\/3TC) clinical trials show robust virologic responses in ART\u2010na\u00efve patients for baseline (BL) viral loads (VL) of over 100 000 c\/mL and<100 000 c\/mL.48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 2008 [Abstract H\u20101251]."},{"key":"e_1_2_5_31_2","first-page":"712","article-title":"Emergence of drug resistance in HIV type 1\u2010infected patients after receipt of first\u2010line highly active antiretroviral therapy","volume":"47","author":"Gupta R","year":"2008","journal-title":"a systematic review of clinical trials"},{"key":"e_1_2_5_32_2","unstructured":"SabinC WormS WeberRet al. Recent use of abacavir and didanosine but not thymidine analogues is associated with risk of myocardial infarction.15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston MA February 2008 [Abstract 957c]."},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"e_1_2_5_34_2","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral\u2010na\u00efve patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00724.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00724.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:56:55Z","timestamp":1696870615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00724.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,22]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00724.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00724.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,22]]}}}